In principle, transient nongenetic modification of a noninfectious gene transfer virus enabling a one time infection and transduction of human cells could eliminate the risk of formation of replication competent virus. Formation of a molecular conjugate vector by conjugation of noninfective ecotropic murine Moloney leukemia virus to polylysine (eMMLV-PL) enabled high-efficiency transduction of human HPC using in vitro and in vivo assays. Xenotransplanted NOD-SCID mice durably expressed the transgene in human leukocytes and human progenitor cells with eMMLV-PL achieving three-fold increased transduction efficiency when directly compared to optimized amphotropic MMLV (aMMLV) transduction. Both aMMLV and eMMLV assembled conjugate vectors showed similar transduction efficiency indicating predominant polylysine-mediated uptake. Integration of retroviral sequences was determined from individual human HPC recovered from eMMLV-PL-xenotransplanted animals. This simple and versatile concept of conjugate gene transfer vectors has the potential to enhance transduction efficiency as well as to improve certain safety aspects of human gene therapy. Moreover, because it permits effective cellular internalization of particles, this concept of molecular conjugates can be used as research tool to investigate the interactions of otherwise noninfectious viruses or modified viral particles at the genomic level.
Introduction
The therapeutic potential for achieving successful stable genetic modification of pluripotent human hematopoietic stem cells is enormous as it could potentially lead to cure of inherited and acquired diseases. Although those scarce cells have unique biological characteristics, on the other side, these may render them one of the most difficult targets for conventional gene transfer approaches. Very low transduction efficiencies as well as loss of transgene expression are major obstacles encountered. 1 The success of human gene therapy depends on effective transfer and durable expression of the desired genes into the target cell at the lowest possible risk for the individual. Current gene therapy concepts employ viral vectors to accomplish stable integration into the genome of hematopoietic progenitor cells (HPC) in order to achieve long-term expression of the transgene in their progeny. The most commonly used vector systems for achieving stable transduction in human cells are retrovirus derived. Most of the experience has been gained with murine Moloney leukemia virus type (MMLV). Specifically, amphotropic MMLV (aMMLV) has been utilized in numerous clinical protocols. More recently, lentiviruses, also members of the retrovirus family, have been explored in human stem cell gene transfer. 2, 3 Human immunodeficiency virus (HIV), the causative retrovirus for AIDS, belongs to the lentivirus family. Unfortunately, retrovirus-based gene transfer to HPC can be associated with potentially serious adverse events. Previously, these concerns were mostly related to the emergence of replication competent retrovirus, although now the over-riding risk is considered to be that of insertional mutagenesis. 4 Recently, two patients participating in a clinical trial developed acute leukemia after their genetic defect of severe combined immunodeficiency had been successfully corrected with recombinant amphotropic MMLV (aMMLV)-mediated replacement in HPC. It is believed that this was the result of oncogene activation caused by retroviral integration into host genome. 5, 6 Nevertheless, despite this setback, given the promising results seen in other participants with a partial correction of this otherwise fatal inherited genetic deficiency, this treatment concept is endorsed in principle. 7 Moreover, despite the difficulties in clearly defining human 'hematopoietic stem cells,' the results suggest that aMMLV indeed is capable to successfully and durably transduce a class of very primitive human HPC. Therefore, the next steps must explore novel approaches to improve the safety of retrovirus-based gene therapy for clinical use. A viral vector's infectivity or cellular uptake is at least in part determined by the presence of natural receptors on the target cells and therefore, cell surface receptor density also largely governs transduction efficiency. [8] [9] [10] [11] [12] [13] Owing to the lack of ecotropic receptors on human cells, unmodified ecotropic retrovirus is not capable of infecting and transducing human cells. We have previously shown in nonhematopoietic human cells that formation of a conjugate vector through transient chemical modification of ecotropic MMLV (eMMLV) by linkage to poly-L-lysine (eMMLV-PL) resulted not only in successful cellular transduction but also in substantially increased transduction efficiency when directly compared to equal moi of unconjugated aMMLV. 14, 15 With this vector, the progeny of transiently modified ecotropic virus could not further propagate in humans due to its inherent tropism restriction. Thus, this vector could provide a significantly improved safety feature over currently used retrovirus vectors. To evaluate the utility of this concept in primary human HPCs, we conducted in vitro and in vivo studies with the ecotropic conjugate vector utilizing in vitro hematopoietic assays as well as the in vivo NOD-SCID xenotransplantation model, which represents one of the best available model to study HPC outside a human.
Methods

Vectors
Construction of the retroviral vectors encoding the G418-resistance gene (neo) has been described elsewhere in detail. 15, 16 The EGFP-encoding retrovirus was constructed by obtaining the EGFP gene from the plasmid pIRES2-EGFP (Clontech, Palo Alto, CA) by restriction digest using the enzymes HindIII and ClaI. The fragment was then inserted into the multiple cloning site of the plasmid pNLCX (Clontech). Backbones of ecotropic and amphotropic retroviral vectors were identical. The sole difference between ecotropic and amphotropic virus were the packaging cell lines (PA317 for amphotropic and GP þ E86 for ecotropic). Generation of retrovirus poly-Llysine conjugates, standardization and quality control were also performed as previously described. 15 Ecotropic or amphotropic murine Moloney leukemia retrovirus (eMMLV or aMMLV) encoding the G418-resistance gene or EGFP were biotinylated (eMMLV-B or aMMLV-B) and linked to streptavidinylated poly-L-lysine (SA-PL) to form ecotropic or amphotropic retrovirus molecular conjugate vectors (eMMLV-PL or aMMLV-PL). Retrovirus was covalently linked to sulfo-N-hydroxysuccinimide-biotin (biotin) following the instructions of the manufacturer (Pierce). Briefly, 0.2 ml of biotin (10 mg/ml in Me 2 SO) was mixed with 2.8 ml of retrovirus in PBS (7 Â 10 7 colony-forming units/ml). The reaction mixture was incubated on ice for 2 h. The product (eMMLV-B) was then exchanged in TES buffer (0.01 M Tris-HCl, pH 7.2, 0.002 M EDTA, 0.15 M NaCl) over EP 10 DG columns (Bio-Rad). eMMLV-B was separated into aliquots and stored in TES at 801C. The titer of eMMLV-B was determined on NIH3T3 monolayers. NeutrAvidin (NA) (Pierce) was covalently linked to PL, molecular mass 30-70 kDa (Sigma), using the heterobifunctional chemical linker EDC (Pierce). Briefly, 10 mg/ml NA was resuspended in HBS and 1.5 ml of NA solution was gently mixed with 0.5 ml of PL (6 mg/ml in HBS) before 0.04 ml of freshly made EDC solution (250 mg/ml in dH2O) was added. The reaction mixture was incubated on ice for 4 h. The product was then dialyzed overnight at 41C against a large volume of PBS using 12-14 kDa cutoff membrane tubing (Spectra/Por, Laguna Hills, CA). The final product, avidin-polylysine was separated into aliquots in PBS and stored at 201C. In some experiments, eMMLV was directly conjugated to poly-L-lysine (PL) (Sigma), molecular mass 30-70 kDa, with EDC.
Cells, culture conditions, and cell transduction Peripheral blood stem cells were obtained after G-CSF mobilization and cytaphersis of the mononuclear fraction from six different normal donors. Primary human bone marrow cells were obtained by standard aspiration from the iliac crest of three healthy voluntary donors. The study had previously been approved by the institutional review board at LSUHSC, New Orleans. Cells were processed using Ficoll gradient (Ficoll-Paque Amersham Pharmacia, Piscataway, NJ). The cell fractions were then enriched for CD34 þ -expressing cells using a cell selection kit purchased from Miltenyi Biotech following instructions provided by the manufacturer (Miltenyi Biotech, Auburn, CA). Flow cytometric analysis was performed for CD34 antigen expression using a directly conjugated PE HPCA-II-CD34 monoclonal antibody (Becton Dickinson, San Jose, CA), directly conjugated FITC-CD45 antibody (Beckman-Coulter, Hialeah, FL), and 7-AAD (7-amino-actinomycin-D, Molecular Probes, Eugene, Oregon) for viability (FacsCalibur Flow cytometer, Becton Dickinson). Purified cells were cultured for 24 h before and 24 h after the transduction in RPMI-1460 (Gibco) supplemented with 20% fetal bovine serum (FBS) (Hyclone, Logan, UT), penicillin/streptomycin (Cellgro Mediatech, Herndon, VA), and 50 ng/ml of rhSCF, rhFlt-3 ligand, and rhIL-6 (Peprotech) or alternatively using medium supplemented with 20% WEHI supernatant. 16 Cells were incubated with retroviral vectors at moi 5 or 20, or an moi of 10 linked as conjugate vector (eMMLV or aMMLV) in serum-reduced conditions for 24 h. During in vitro culture, cells were maintained at 371C under a 5% CO 2 atmosphere in a humidified incubator. Control amphotropic vector transductions with unlinked aMMLV were performed using spinoculation at moi 20 in cytokine-supplemented medium with 8 mg of polybrene/ml (Sigma) at a cell density of 5 Â 10 5 /ml. The cells were spun at 2500 g at room temperature for 3 h as described. 17 Cells were resuspended in cytokine supplemented medium with 10% FCS and a second transduction was performed 24 h later prior to using cells for transplantation or long-term culture experiments. Long-term bone marrow cultures were performed as previously described. 18 Briefly, after in vitro transduction, CD34 þ selected cells were maintained in cytokine supplemented medium. After 6 weeks of in vitro culture, colony-forming unit assays for human progenitors (CFU) were performed using premade soft agar (human Stemline Complete Methylcellulose Medium with Epo, Sigma, St Louis, MO).
Animals NOD/LtSz-scid/scid (NOD/SCID) mice 19 were originally purchased from JAX laboratories (Bar Harbor, ME), bred and maintained under specific pathogen-free conditions in the animal facility of the LSUHSC. The project was approved by the local animal use committee. Mice, 8-week old, were irradiated with a sublethal dose of 200 cGy from a 137 Cs source in two fractions 6 h apart, which was administered 24 h before intravenous injection with 2 Â 10 7 human CD34 þ selected cells. Upon being killed 8 weeks after transplantation, blood, bone marrow, and spleen cells were harvested and cells were maintained in ice-cold Hanks' balanced salt solution supplemented with 5% fetal calf serum (Hyclone) plus 5% pooled normal human serum (Sigma) until further analysis.
Genomic integration analysis
Cells obtained from blood or from meshed hematopoietic organs of xenotransplanted NOD/SCID mice were hemolysed. Human Fc receptors were blocked by incubation with 5% normal human serum; blockade of murine Fc receptors was carried out in a second incubation step using 2% mouse serum (Sigma, St Louis, MO). Cells were stained with human CD45-PE (Becton and Dickinson, San Jose, CA). The cells were then analyzed by flow cytometry and the total number of human cells as well as the proportion of human cells expressing EGFP was determined. Human cells from in vitro studies or heterogeneous cell preparations (human/murine) from xenotransplanted NOD-SCID mice were plated in murine Stemline Complete Methylcellulose Medium with Epo (Sigma Louis, MO). This product supports human and murine colony formation equally well. After 10 days, the plates were scored for total colony numbers as well as the proportion of EGFP transgene-expressing colonies using UV transmission microscopy. To quantitatively discriminate murine from human colonies from xenotransplanted animals within a culture dish, individual colonies were picked from plates to determine their species origin via molecular analysis. Human and human EGFP-transduced colonies were identified using previously established protocols. DNA from individual colonies was analyzed for the presence of human b-microglobulin sequences as well as for presence of EGFP gene sequences. 20, 21 These molecular data were compared to total colony counts and the percentage of green or EGFP-expressing colonies. For DNA purification, kit reagents obtained from Invitrogen were used (Carlsbad, CA). This analysis allowed determination of the ratio of plated human vs mouse colonies. Moreover, it also allowed establishment of the ratio of transduced, transgene-expressing human colonies vs transduced but not transgene-expressing human colonies. Integration analysis for retroviral sequences was performed using inverse PCR using a previously published protocol with slight modification. 22, 23 Genomic DNA extracted from individual colonies was digested with Taq I (NEB Beverly, MA) for 2 h at 651C following RNAse treatment (Invitrogen). The DNA digest was then incubated overnight with T4 ligase at 161C (NEB, Beverly, MA). The resulting circularized DNA was then amplified using the primers INVa (5 0 AGG AAC TGC TTA CCA CA 3 0 ) and INVb (5 0 CTG TTC CTT GGG AGG GT 3 0 ) (IDT Coralville, IA) (951C Â 5 min followed by 35 cycles 951C Â 60 s, 501C Â 2 min and 721C Â 4 min). Nested PCR was then performed using the amplification product as template with the primers INVc (5 0 TCC TGA CCT TGA TCT GA 3 0 ) and INVd (5 0 CTG AGT GAT TGA CTA CC 3 0 ) (IDT). Amplification conditions were identical as described for the first PCR reaction. The resulting nested PCR products were electrophoresed on a 2% agarose gel (Sigma, St Louis, MO).
Quantitative real-time PCR
The primers and probes were designed by ABI Primer Express software (PE Biosystems, Roche, Branchburg, NJ). A unique and specific 71-base pair sequence of the EGFP gene was amplified using the primers 5 0 -CCG ACC ACA TGA AGC AGC ACG ACT-3 0 (forward), 5 0 -GAT GGT GCG CTC CTG GAC-3 0 (reverse), and 5 0 -FAM-TCA AGT CCG CCA TGC CCG-TAMRA-3 0 (probe). The TaqMan Universal PCR Master Mix Kit was used following amplification protocols supplied by the manufacturer (PE Biosystems). DNA standards were prepared by concomitant amplification of DNA extracted from a retrovirally stably transduced NIH3T3 clone and the plasmid pNL-EGFP. Real-time PCR was conducted on a ABI PRISM 7700 Sequence Detector (PE Biosystems) as previously published in detail by our group. 14, 15, 24 The samples were analyzed with the SDS 1.9.1 software (ABI PRISM s sequence detection system 1.9.1, PE Biosystems, Foster City, CA) and corrected for total DNA content using a spectrophotometer (DU640B, Beckman Instruments).
Statistical analysis
Means of data were calculated by ANOVA with Fisher's follow-up testing. All calculations were performed by using mathematical functions embedded into the statistical software program 'Statview' (Calabasas, CA). A value of Pp0.05 was considered statistically significant.
Results
Human hematopoietic progenitor cells are effectively transduced by eMMLV conjugated to poly-L-lysine (eMMLV-PL) Human CD34 þ selected bone marrow-derived mononuclear cells were transduced with three different vectors encoding the neomycin gene, conventional amphotropic MMLV (aMMLV) at moi 5 and 20, the amphotropic polylysine conjugate vector (aMMLV-PL), and ecotropic polylysine conjugate vector (eMMLV-PL) using the above-described transduction conditions. The polylysine conjugate vectors were standardized to have the equivalent of moi 10 of retrovirus particles. Cells for these experiments were obtained from six different individual donors. aMMLV resulted in 14 and 19% of G418-resistant colonies at moi 5 and 20, respectively, while polylysine conjugation of either virus type lead to approximately 50% of G418-resistant colonies (Figure 1a) . To compare the capacity for these conjugate vectors in transducing more primitive hematopoietic precursor cells, long-term cultures of CD34 þ selected cells were performed. In all, 9 and 14% of G418-resistant colonies were observed after transduction with aMMLV with moi of 5 and 20, respectively; polylysine conjugation leads to 44 and 42% of G418-resistant colonies following eMMLV-PL and aMMLV-PL transduction, respectively ( Figure 1b) . As expected, unmodified eMMLV did not result in transduction of human hematopoietic progenitor cells despite employment of moi 100 as no G418-resistant colonies were detected.
Primitive NOD repopulating human hematopoietic cells are effectively transduced with the ecotropic MMLV polylysine conjugate vector eMMLV-PL To demonstrate the capacity of eMMLV-PL to stably transduce human NOD repopulating hematopoietic cells, which can differentiate in vivo, NOD-SCID mice were xenotransplanted with human CD34 þ cells following gene transfer with the ecotropic conjugate vector. Another group of animals was transplanted with CD34 þ selected cells transduced with aMMLC following a sequential spinoculation protocol. At 8 weeks after the transplantation, hematopoietic tissues were analyzed with flow cytometry by staining for the human differentiation marker CD45 and for EGFP-expressing human cells. Figure 2 demonstrates a typical flow cytometry diagram obtained on peripheral blood and spleens of two animals, each of which had been transplanted with eMMLV-PLtransduced CD34 þ cells that were obtained from different donors.
To evaluate the frequency of total human and transduced human precursor cells in mouse bone marrow and spleen, clonogenic assays were performed on cells recovered from these organs. Colonies were counted and the percentage of green colonies determined. Owing to the chimerism of human and murine hematopoiesis within these animals, in vitro colony formation was supported from progenitor cells derived from both species. Therefore, individual colonies were picked quantitatively and analyzed for presence of human b-microglobulin, a marker specific for human cells, which allows the discrimination between human and murine origin in xenotransplanted animals. 20 The percentage of human cells in spleen and bone marrow, respectively, was 39% (710%) and 17% (76%) in animals transplanted with eMMLV-PL-transduced human cells and 39% (712%) and 14% (77%) in the aMMLV-transduced group. There was no significant difference in the level of human engraftment between groups transduced with different vectors. However, the proportion of human cells in spleens was significantly higher than in bone marrow (Figure 3a) . EGFP transgene expression in human cells was 38% (710%) and 22% (78%) of colonies in spleen and bone marrow of eMMLV-PL-transplanted animals as determined by transmission microscopy. In aMMLV-transduced human cell transplanted animals, EGFP expression in human colonies was 13% (75%) and 6% (74%) in spleen and bone marrow, respectively (Figure 3b) . However, molecular analysis for EGFP sequences revealed a somewhat higher percentage of eMMLV-PL-transduced human colonies than transgene protein expression (54712 and 49711%) in both spleen and bone marrow, respectively. Similarly, in aMMLVtransduced cells, EGFP sequences were also detected at a higher rate compared to EGFP expression, with 2078 and 1475% in spleen and bone marrow-derived human cells (Figure 3c ).
Ecotropic MMLV conjugated to polylysine integrates into the genome of human NOD repopulating cells
To demonstrate whether integration into the host genome occurred with the eMMLV-PL vector, EGFP-expressing colonies recovered from hematopoietic organs of three different xenotransplanted animals were subjected to a previously described inverse PCR procedure. 22, 23 This specific PCR reaction amplifies integrated proviral sequences with their host genome junction fragments. The size of the amplification product depends on the s ite of retroviral integration into the host genome and varies with the location of specific enzymatic restriction sites occurring within the host genome relative to the provirus. Therefore, since individual integration events are unique, in many instances they will lead to amplification products variable in size, which are either smaller or larger than a control viral plasmid. Clonal genomic integration analysis of ecotropic MMLVpolylysine conjugate-transduced human hematopoietic progenitor colonies. Single cell derived human EGFP-expressing colonies were recovered from spleens and bone marrow of xenotransplanted NOD-SCID mice and evaluated for genomic integration with a previously described inverse PCR protocol. The PCR amplification products were separated in a 2% agarose gel by electrophoresis, which is depicted after ethidum bromide staining. Lane 1 was loaded with a standardized size marker. Lanes 2-8 represent different individual EGFP-expressing colonies. Lane 9 represents the amplification product of the retrovirus plasmid pLN.
To determine the copy number of integration per cell, five individual human EGFP-expressing colonies were picked and analyzed by real-time PCR. An average of 0.93 copies of EGFP per cells was determined, which approximates one copy per cell ( Figure 5) .
Discussion
Our findings demonstrate that the conjugate vector eMMLV-PL constructed of ecotropic MMLV physically linked to poly-L-lysine effectively transduces human hematopoietic progenitor cells with LTC-IC capacity as well as human NOD-SCID repopulating cells. The data provided also show that polylysine conjugation significantly enhances transduction of human HPC with aMMLV by three-fold when compared to unconjugated aMMLV under optimized transduction conditions. In respect to their molecular makeup and handling throughout the experiments, vectors were identical with the only difference being the packaging cell lines. Similar to our previous studies in nonhematopoietic cells, the eMMLV-PL vector also lead to genomic integration in human progenitor cells with NOD-SCID repopulating potential at frequency of one copy per cell. In our previous studies, we also reported that formation of amphotropic retrovirus polylysine conjugates (aMMLV-PL) substantially enhanced transduction efficiency over unconjugated aMMLV. When both amphotropic and ecotropic polylysine conjugates were compared directly in nonhematopoietic cells, we reported that each conjugate vector transduced cells equally well. 14, 15 Such comparative studies for eMMLV-PL and aMMLV-PL were not performed with human HPC. However, it is conceivable that formation of polylysine conjugates with aMMLV would also lead to enhanced transduction of HPC. The data suggest that the predominant pathway for vector uptake, once conjugated, occurs exclusively via the polylysine cell interaction and completely overrides the potentially competing natural tropism of aMMLV that is also present within the conjugate.
Admixture of positively charged polycations such as Polybrene in retroviral gene transfer protocols has long been known to nonspecifically promote retrovirus transduction efficiency. 25, 26 Similarly, the addition of fibronectin fragments augments retrovirus transduction efficiency. [27] [28] [29] [30] Although the exact mechanisms for these transduction enhancements are not completely understood for either molecule, it is believed that they augment virus infectivity, which leads to improved cellular virus uptake. This improved virus uptake could occur via the natural receptor; however, it could also be via utilization of an alternate pathway. Since the addition of fibronectin or polybrene does not enable ecotropic MMLV (eMMLV) transduction of human cells, the establishment of an alternate pathway would be an unlikely mechanism. It would rather indicate the enhancement of already existing entry pathways, such as augmentation of aMMLV via its natural receptor. This proposed concept is consistent with previous reports demonstrating fibronectin to increase local virus titer through colocalization of retrovirus particles and target cells. [27] [28] [29] [30] In contrast, the actual physical linkage of ecotropic MMLV to the polycation poly-L-lysine enables efficient cellular uptake of ecotropic retrovirus. Thus, this new mechanism completely overcomes receptor-dependent virus tropism. Previous work established positively charged polylysine to nonspecifically penetrate cell surface membranes, thereby enabling cytosol entry. 31, 32 Polylysine can also bind to cell surface heparin receptors enabling entry via this pathway. [31] [32] [33] Since retrovirus conjugates are made up of multiple virus particles physically bound to polylysine, it is likely that uptake of this vector would enhance the possibility of intact virus reaching the nucleus. It is also likely that polylysine conjugation confers enhanced viral resistance from intracellular particle degradation. For instance, Wu et al. showed that transfected DNA bound to polylysine was protected from intracellular nuclease digestion. 34 It is possible that polylysine conglomerate formation confers a similar protective effect from cytosolic degradation to conjugated retrovirus particles. Finally, conjugate formation might also induce other additional mechanisms affecting gene expression. For instance, a slightly higher proportion of eMMLV-PL EGFP PCR-positive cells express the transgene when compared to aMMLV-transduced cells. Statistical evaluation of these data did not reveal significance although the experiments were not designed to investigate such a difference. Therefore, this observation needs further investigation.
Viruses that are currently employed for human gene therapy protocols depend on either their natural tropism or on certain genetic alterations to infect human cells. An example for genetic modification would be pseudotyping for instance with the vesicular stomatitis virus envelope. In the event of the emergence of replication competent virus, the progeny arising from viruses with inherent tropism for human cells will maintain infectivity to human cells. This feature carries the risk of viral propagation and consequently a systemic viral infection of the affected patient. The event of in vivo formation of replication competent virus is a serious and feared complication of gene therapy in man. It poses a significant safety risk as it can promote malignant transformation of lymphoid tissues as previously reported in non-human primate trials. 35 Since ecotropic virus cannot infect human cells, occurrence of an event leading to the formation of replication competent ecotropic virus in humans would be theoretically a self-limited problem. Since the conjugation process does not alter the virus genetically, its progeny would remain of ecotropic type. Therefore, a transient tropism modification with polylysine of a virus noninfectious to human cells minimizes the risk for the emergence of a replication competent virus and its potential adverse clinical consequences to patients.
So far, numerous aMMLV employing gene therapy clinical trials have been conducted without the emergence of replication competent retrovirus being reported. Therefore, the argument could be made that this concern might be over-rated. However, when compared to the non-human primate experience, comparatively low titers were employed in human trials and transduction of target cells was also minimal. Moreover, most participating subjects had terminal diseases and for that reason only very limited long-term data are available from these studies. Although clinical outcomes resulting from the emergence of replication competent MMLV in humans are still unknown, other retrovirus vectors, especially of the lentivirus subtype, likely might lead to serious consequences such as emergence of AIDS. In AIDS patients who are more likely to be treated with novel lentiviral vectors because they are already infected with HIV, recombination events with replication competent vector could lead to emergence of new and resistant virus strains. 3, 36 These possibilities are of concern, especially for patients with longer life expectancy as well as from a public health perspective. With HIV-derived lentiviral vectors being close to entering clinical trials, this concept of conjugate vectors would allow the introduction of an additional barrier making formation of replication competent virus even less likely. Although the data provide proof of principle for this concept, additional studies will be required to better characterize the system. Moreover, with its ability to introduce noninfective viruses efficiently into cells lacking the natural receptor, the conjugate vector system could also become a useful research tool for virology and gene therapy. For instance, it could enable researchers to study gene expression and genomic integration of mutated or synthetic viruses in noninfective cell lines.
In summary, there are several serious safety concerns with the use of integrating retrovirus-based vectors in human gene therapy, which need to be addressed independently. We demonstrated that polylysine-based retroviral conjugate vectors can overcome natural tropism barriers associated with low or lack of virus receptor expression on target cells. Moreover, conjugation to polylysine significantly enhances retroviral transduction of primitive HPC. This system could reduce the risk of formation of replication competent virus with it theoretically becoming a self-limited problem. In principle, this concept of vector conjugate formation could be explored for broader applications in the field of virus-based gene vectors.
